SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Richard T. Penson, Kathleen M. Moore, Gini F. Fleming, Patricia Braly, Veronica Schimp, Hoa Nguyen, Ursula A. Matulonis, Susana Banerjee, Paul Haluska, Martin Gore, Diane C. Bodurka, Rebecca R. Hozak, Adarsh Joshi, Yihuan Xu, Jonathan D. Schwartz, William P. McGuire, A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, Gynecologic Oncology, 2014, 134, 3, 478

    CrossRef

  2. 2
    Cristiano Ferrario, Gerald Batist, Advances in the approach to novel drug clinical development for breast cancer, Expert Opinion on Drug Discovery, 2014, 9, 6, 647

    CrossRef

  3. 3
    Fahimeh Ghavamipour, S. Shirin Shahangian, Reza H. Sajedi, S. Shahriar Arab, Kamran Mansouri, Mahmoud Reza Aghamaali, Development of a highly-potent anti-angiogenic VEGF8–109 heterodimer by directed blocking of its VEGFR-2 binding site, FEBS Journal, 2014, 281, 19
  4. 4
    I. Pastushenko, P.B. Vermeulen, G.G. Van den Eynden, A. Rutten, F.J. Carapeto, L.Y. Dirix, S. Van Laere, Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications, British Journal of Dermatology, 2014, 171, 2
  5. 5
    Tetsuro Ohba, Justin M.M. Cates, Heather A. Cole, David A. Slosky, Hirotaka Haro, Jiro Ichikawa, Takashi Ando, Herbert S. Schwartz, Jonathan G. Schoenecker, Pleiotropic effects of bisphosphonates on osteosarcoma, Bone, 2014, 63, 110

    CrossRef

  6. 6
    Marco Bartolotti, Enrico Franceschi, Rosalba Poggi, Alicia Tosoni, Monica Di Battista, Alba A Brandes, Resistance to antiangiogenic therapies, Future Oncology, 2014, 10, 8, 1417

    CrossRef

  7. 7
    A J C Pommier, R Shaw, S K M Spencer, S R Morgan, P M Hoff, J D Robertson, S T Barry, J M Jürgensmeier, Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib, British Journal of Cancer, 2014, 111, 8, 1590

    CrossRef

  8. 8
    L G M Daenen, J M Houthuijzen, G A Cirkel, J M L Roodhart, Y Shaked, E E Voest, Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies, Oncogene, 2014, 33, 11, 1341

    CrossRef

  9. 9
    M. Tsagkataki, T. Papathomas, D. Lythgoe, A. Kamal, Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion*, Seminars in Ophthalmology, 2014, 1

    CrossRef

  10. 10
    Toyonori Tsuzuki, Naoto Sassa, Yoshie Shimoyama, Takamitsu Morikawa, Ryoichi Shiroki, Makoto Kuroda, Akitoshi Fukatsu, Kyoko Kuwahara, Yasushi Yoshino, Ryohei Hattori, Momokazu Gotoh, Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism, Histopathology, 2014, 64, 4
  11. 11
    A. Favia, M. Desideri, G. Gambara, A. D'Alessio, M. Ruas, B. Esposito, D. Del Bufalo, J. Parrington, E. Ziparo, F. Palombi, A. Galione, A. Filippini, VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling, Proceedings of the National Academy of Sciences, 2014, 111, 44, E4706

    CrossRef

  12. 12
    Gi Kim, Oug Cheong, Song Bae, Jongheon Shin, Sang Lee, 6″-Debromohamacanthin A, a Bis (Indole) Alkaloid, Inhibits Angiogenesis by Targeting the VEGFR2-Mediated PI3K/AKT/mTOR Signaling Pathways, Marine Drugs, 2013, 11, 4, 1087

    CrossRef

  13. 13
    K Danza, B Pilato, R Lacalamita, T Addati, F Giotta, A Bruno, A Paradiso, S Tommasi, Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer, European Journal of Human Genetics, 2013, 21, 8, 824

    CrossRef